Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oncternal Therapeutics, Inc.

0.5266
0.0000
Volume:- -
Turnover:- -
Market Cap:1.56M
PE:-0.05
High:0.5266
Open:0.5266
Low:0.5266
Close:0.5266
52wk High:4.43
52wk Low:0.5266
Shares:2.96M
Float Shares:2.71M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.6916
EPS(LYR):-13.4282
ROE:-149.86%
ROA:-74.11%
PB:0.17
PE(LYR):-0.04

Loading ...

Oncternal Therapeutics Inc Intent To Voluntarily Delist From Nasdaq And Deregister With SEC

Reuters
·
Mar 08

Top Premarket Decliners

MT Newswires Live
·
Nov 25, 2024

Oncternal Therapeutics to Cut Most of Its Workforce

Dow Jones
·
Nov 15, 2024

Oncternal Therapeutics Inc: Announces Workforce Reduction Effective December 2, 2024

THOMSON REUTERS
·
Nov 15, 2024

Oncternal Therapeutics Inc: Four Oncternal Employees Will Remain in a Part-Time Capacity in Connection With Exploration of Strategic Alternatives

THOMSON REUTERS
·
Nov 15, 2024

Oncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview

Reuters
·
Nov 06, 2024

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

THOMSON REUTERS
·
Oct 22, 2024

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire
·
Oct 22, 2024

Oncternal Therapeutics Cuts Jobs, Discontinues Product Development Amid Business Review

Dow Jones
·
Sep 13, 2024

BRIEF-Oncternal Therapeutics Workforce Reduction Of About 10 Employees

Reuters
·
Sep 13, 2024

Oncternal Therapeutics : Workforce Reduction of About 10 Employees

THOMSON REUTERS
·
Sep 13, 2024

Oncternal Therapeutics : in Connection With Workforce Reduction, Salim Yazji Will Cease Serving as Chief Medical Officer

THOMSON REUTERS
·
Sep 13, 2024

Sector Update: Health Care Stocks Rise in Thursday Trading

MT Newswires Live
·
Sep 13, 2024

Oncternal Therapeutics Cut to Hold From Buy by Brookline Capital

Dow Jones
·
Sep 12, 2024

Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall

MT Newswires Live
·
Sep 12, 2024

Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall

MT Newswires Live
·
Sep 12, 2024

Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy

MT Newswires Live
·
Sep 12, 2024

Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy

MT Newswires Live
·
Sep 12, 2024

BUZZ-Oncternal hits record low on plans to scrap studies, explore strategic alternatives;

Reuters
·
Sep 12, 2024

Oncternal Therapeutics Shares Hit Record Low as Co to Scrap Studies, Explore Strategic Alternatives, Last Down 58.6% at $1.72

THOMSON REUTERS
·
Sep 12, 2024